Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SiCARIO: Adaptive Radioimmunotherapy for NSCLC
NCT05501665Phase 2Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- May 2023
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in non-small cell lung cancer (NSCLC) (11 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Incidence of adverse events at 2 years and Best overall response rate at 6 months. Started May 2023; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05501665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501665.